7 results
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
6.11.16,18,31,33,45,52,58) 0.5mL IM ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
20 mg/kg IV or IM ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Candidiasis in HIV-AIDS ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Chagas Disease Note ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Treponema pallidum Infections (Syphilis) to Prevent Disease in HIV-AIDS
Early Stage (Primary, Secondary,
Prevent Disease in HIV-AIDS ... consultation to guide management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
skin and/or lymph nodes ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
Note: Active TB ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology